Moltzan, C. J., Anderson, D. A., Callum, J., Fremes, S., Hume, H., Mazer, C. D., Poon, M. C., Rivard, G., Rizoli, S., & Robinson, S. (2008). The evidence for the use of recombinant factor VIIa in massive bleeding: Development of a transfusion policy framework. Transfusion Medicine, 18(2), 112-120. https://doi.org/10.1111/j.1365-3148.2008.00846.x
The evidence for the use of recombinant factor VIIa in massive bleeding: Development of a transfusion policy framework. / Moltzan, C. J.
; Anderson, D. A.; Callum, J. et al.
En:
Transfusion Medicine, Vol. 18, N.º 2, 04.2008, p. 112-120.
Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva
Moltzan, CJ, Anderson, DA, Callum, J, Fremes, S, Hume, H, Mazer, CD, Poon, MC, Rivard, G, Rizoli, S & Robinson, S 2008, 'The evidence for the use of recombinant factor VIIa in massive bleeding: Development of a transfusion policy framework', Transfusion Medicine, vol. 18, n.º 2, pp. 112-120. https://doi.org/10.1111/j.1365-3148.2008.00846.x
Moltzan CJ, Anderson DA, Callum J, Fremes S, Hume H, Mazer CD et al. The evidence for the use of recombinant factor VIIa in massive bleeding: Development of a transfusion policy framework. Transfusion Medicine. 2008 abr.;18(2):112-120. doi: 10.1111/j.1365-3148.2008.00846.x
Moltzan, C. J. ; Anderson, D. A. ; Callum, J. et al. / The evidence for the use of recombinant factor VIIa in massive bleeding : Development of a transfusion policy framework. En: Transfusion Medicine. 2008 ; Vol. 18, N.º 2. pp. 112-120.
@article{dac20a82401e47a9b309253c7cf9cb4d,
title = "The evidence for the use of recombinant factor VIIa in massive bleeding: Development of a transfusion policy framework",
abstract = "A review of the recent randomized control trial evidence of the use of recombinant factor VIIa (rFVIIa) in massive bleeding. rFVIIa is a recombinant genetically engineered clotting factor that has been used for the management of haemophilia patients with inhibitors. There has been increasing use in patients with massive bleeding, even when there is no underlying coagulation disorder present. In November 2006, the Canadian National Advisory Committee on Blood and Blood Products engaged in a consultation and review process with several leading Canadian experts to review and discuss the current evidence up to November 2006. There is little evidence to support the routine use of rFVIIa in massive bleeding on review of 13 randomized controlled trials. rFVIIa should only be considered as part of a transfusion policy framework for massive bleeding after all other transfusion and supportive measures are considered. An example of a policy framework is presented.",
author = "Moltzan, {C. J.} and Anderson, {D. A.} and J. Callum and S. Fremes and H. Hume and Mazer, {C. D.} and Poon, {M. C.} and G. Rivard and S. Rizoli and S. Robinson",
year = "2008",
month = apr,
doi = "10.1111/j.1365-3148.2008.00846.x",
language = "English",
volume = "18",
pages = "112--120",
journal = "Transfusion Medicine",
issn = "0958-7578",
publisher = "Wiley-Blackwell",
number = "2",
}
TY - JOUR
T1 - The evidence for the use of recombinant factor VIIa in massive bleeding
T2 - Development of a transfusion policy framework
AU - Moltzan, C. J.
AU - Anderson, D. A.
AU - Callum, J.
AU - Fremes, S.
AU - Hume, H.
AU - Mazer, C. D.
AU - Poon, M. C.
AU - Rivard, G.
AU - Rizoli, S.
AU - Robinson, S.
PY - 2008/4
Y1 - 2008/4
N2 - A review of the recent randomized control trial evidence of the use of recombinant factor VIIa (rFVIIa) in massive bleeding. rFVIIa is a recombinant genetically engineered clotting factor that has been used for the management of haemophilia patients with inhibitors. There has been increasing use in patients with massive bleeding, even when there is no underlying coagulation disorder present. In November 2006, the Canadian National Advisory Committee on Blood and Blood Products engaged in a consultation and review process with several leading Canadian experts to review and discuss the current evidence up to November 2006. There is little evidence to support the routine use of rFVIIa in massive bleeding on review of 13 randomized controlled trials. rFVIIa should only be considered as part of a transfusion policy framework for massive bleeding after all other transfusion and supportive measures are considered. An example of a policy framework is presented.
AB - A review of the recent randomized control trial evidence of the use of recombinant factor VIIa (rFVIIa) in massive bleeding. rFVIIa is a recombinant genetically engineered clotting factor that has been used for the management of haemophilia patients with inhibitors. There has been increasing use in patients with massive bleeding, even when there is no underlying coagulation disorder present. In November 2006, the Canadian National Advisory Committee on Blood and Blood Products engaged in a consultation and review process with several leading Canadian experts to review and discuss the current evidence up to November 2006. There is little evidence to support the routine use of rFVIIa in massive bleeding on review of 13 randomized controlled trials. rFVIIa should only be considered as part of a transfusion policy framework for massive bleeding after all other transfusion and supportive measures are considered. An example of a policy framework is presented.
UR - http://www.scopus.com/inward/record.url?scp=42049123281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42049123281&partnerID=8YFLogxK
U2 - 10.1111/j.1365-3148.2008.00846.x
DO - 10.1111/j.1365-3148.2008.00846.x
M3 - Review article
C2 - 18399845
AN - SCOPUS:42049123281
SN - 0958-7578
VL - 18
SP - 112
EP - 120
JO - Transfusion Medicine
JF - Transfusion Medicine
IS - 2
ER -